Conray 400

Generic name: Iothalamate Sodium
Dosage form: Injection
Drug class:Ionic iodinated contrast media

Medically reviewed by Drugs.com. Last updated on Dec 22, 2021.

January 1998

Mallinckrodt Inc.

NOT FOR INTRATHECAL USE

Conray 400 Description

Conray 400 is a sterile aqueous solution intended for intravascular administration as a diagnostic radiopaque medium. Conray 400 contains 66.8% w/v of iothalamate sodium which is monosodium 5-acetamido-2,4,6-triiodo-N-methylisophthalamate and has the following structural formula:

Each milliliter contains 668 mg of iothalamate sodium, 0.110 mg edetate calcium disodium as a stabilizer and 0.125 mg of monobasic sodium phosphate as a buffer. The solution contains approximately 24.2 mg (1.05 mEq) sodium in each milliliter of solution and provides 40% (400 mg/mL) organically bound iodine. Conray 400 has an osmolarity of approximately 1700 mOsmol per liter, an osmolality of approximately 2300 mOsmol per kilogram and is, therefore, hypertonic under conditions of use. The viscosity (cps) is approximately 7 at 25°C and 4.5 at 37°C. The pH is 6.5-7.7. Conray 400 is a clear solution containing no undissolved solids. Crystallization does not occur at normal room temperatures. It is supplied in containers from which the air has been displaced by nitrogen.

Conray 400 - Clinical Pharmacology

Following intravascular injection, Conray 400 is rapidly transported through the circulatory system to the kidneys and is excreted unchanged in the urine by glomerular filtration. The pharmacokinetics of intravascularly administered radiopaque contrast media are usually best described by a two compartment model with a rapid alpha phase for drug distribution and a slower beta phase for drug elimination. In patients with normal renal function, the alpha and beta half-lives of Conray 400 were approximately 10 and 90 minutes.

Angiography may be performed following intravascular injection which will permit visualization until significant hemodilution occurs.

Renal accumulation is sufficiently rapid that maximum radiographic density in the calyces and pelves occurs in most instances about 3-8 minutes after injection. In patients with impaired renal function, ...